Can India’s pharmaceutical industry achieve self-reliance in APIs? by Chetan Shah, COO, Senores Pharmaceuticals
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Announces Rs. 317 crore investment in new recycling plant
Overall investment in the US facility is estimated around US$50 million
403 entries from 22 states covering 168 districts highlight groundbreaking initiatives vital to improving national nutrition metrics.
There are 38.4 million people with diabetes in the United States
Biocon Foundation has been steadfast in its mission to empower underserved communities through innovative healthcare solutions, education, and sustainable development initiatives
This is Senores' second API manufacturing facility adding significantly to the existing API manufacturing capabilities.
MET-X, a novel metallo-beta-lactamase (MBL) inhibitor, has shown best-in-class performance in preclinical studies
Eleven CRDMOs collaborate to form IPSO with the aim to elevate India’s position in the global pharmaceutical value-chain
YESINTEK is approved for the treatment of Crohn’s disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis
Subscribe To Our Newsletter & Stay Updated